CN114929232A - 一种吡啶并嘧啶类衍生物的结晶形式及其制备方法 - Google Patents

一种吡啶并嘧啶类衍生物的结晶形式及其制备方法 Download PDF

Info

Publication number
CN114929232A
CN114929232A CN202080091758.4A CN202080091758A CN114929232A CN 114929232 A CN114929232 A CN 114929232A CN 202080091758 A CN202080091758 A CN 202080091758A CN 114929232 A CN114929232 A CN 114929232A
Authority
CN
China
Prior art keywords
formula
compound
solvent
crystalline form
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080091758.4A
Other languages
English (en)
Other versions
CN114929232B (zh
Inventor
吴琪
杜振兴
王捷
王林
陆伟栋
邵启云
冯君
贺峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN114929232A publication Critical patent/CN114929232A/zh
Application granted granted Critical
Publication of CN114929232B publication Critical patent/CN114929232B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

一种吡啶并嘧啶类衍生物的结晶形式及其制备方法，具体而言，涉及式(I)化合物的结晶形式及制备方法。新晶型具备良好的理化性质，更有利于临床治疗。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN202080091758.4A 2020-01-02 2020-12-31 一种吡啶并嘧啶类衍生物的结晶形式及其制备方法 Active CN114929232B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020100028229 2020-01-02
CN202010002822 2020-01-02
PCT/CN2020/142037 WO2021136488A1 (zh) 2020-01-02 2020-12-31 一种吡啶并嘧啶类衍生物的结晶形式及其制备方法

Publications (2)

Publication Number Publication Date
CN114929232A true CN114929232A (zh) 2022-08-19
CN114929232B CN114929232B (zh) 2023-06-16

Family

ID=76686512

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080091758.4A Active CN114929232B (zh) 2020-01-02 2020-12-31 一种吡啶并嘧啶类衍生物的结晶形式及其制备方法

Country Status (10)

Country Link
US (1) US20230058425A1 (zh)
EP (1) EP4085914A4 (zh)
JP (1) JP2023509175A (zh)
KR (1) KR20220123437A (zh)
CN (1) CN114929232B (zh)
AU (1) AU2020416484A1 (zh)
CA (1) CA3163386A1 (zh)
MX (1) MX2022008286A (zh)
TW (1) TW202128692A (zh)
WO (1) WO2021136488A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202245782A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 一種包含吡啶并嘧啶類衍生物的醫藥組成物及其製備方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017048727A1 (en) * 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
CN107108615A (zh) * 2015-03-04 2017-08-29 吉利德科学公司 Toll样受体调节性4,6‑二氨基‑吡啶并[3,2‑D]嘧啶化合物
WO2019166532A1 (en) * 2018-03-01 2019-09-06 Janssen Sciences Ireland Unlimited Company 2,4-diaminoquinazoline derivatives and medical uses thereof
CN110526918A (zh) * 2018-05-25 2019-12-03 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的晶型及制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001291817A1 (en) 2000-09-26 2002-04-08 Tan, May Chuagnesanna Composition comprising a fat phase, vegetable matter and salt
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
PL2268618T3 (pl) 2008-03-03 2015-11-30 Novartis Ag Związki i kompozycje jako modulatory aktywności receptorów TLR
EA023536B1 (ru) 2009-08-07 2016-06-30 Глаксосмитклайн Байолоджикалс Са Производные оксоаденина, конъюгированные с фосфо- или фосфонолипидами
JP2013512859A (ja) 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
CN103118682A (zh) 2010-04-30 2013-05-22 加利福尼亚大学校务委员会 合成tlr7激动剂的磷脂缀合物的用途
US8440662B2 (en) * 2010-10-31 2013-05-14 Endo Pharmaceuticals, Inc. Substituted quinazoline and pyrido-pyrimidine derivatives
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
WO2013033345A1 (en) 2011-08-30 2013-03-07 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
WO2014022728A1 (en) 2012-08-02 2014-02-06 Endo Pharmaceuticals, Inc Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer
WO2017046112A1 (en) 2015-09-17 2017-03-23 F. Hoffmann-La Roche Ag Sulfinylphenyl or sulfonimidoylphenyl benzazepines
WO2018045150A1 (en) * 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CA3105286A1 (en) * 2018-07-03 2020-01-09 Guobao Zhang Pyridopyrimidine derivative, preparation method therefor and medical use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108615A (zh) * 2015-03-04 2017-08-29 吉利德科学公司 Toll样受体调节性4,6‑二氨基‑吡啶并[3,2‑D]嘧啶化合物
WO2017048727A1 (en) * 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
WO2019166532A1 (en) * 2018-03-01 2019-09-06 Janssen Sciences Ireland Unlimited Company 2,4-diaminoquinazoline derivatives and medical uses thereof
CN110526918A (zh) * 2018-05-25 2019-12-03 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的晶型及制备方法

Also Published As

Publication number Publication date
WO2021136488A1 (zh) 2021-07-08
EP4085914A1 (en) 2022-11-09
JP2023509175A (ja) 2023-03-07
KR20220123437A (ko) 2022-09-06
MX2022008286A (es) 2022-08-08
EP4085914A4 (en) 2023-06-21
CA3163386A1 (en) 2021-07-08
TW202128692A (zh) 2021-08-01
CN114929232B (zh) 2023-06-16
AU2020416484A1 (en) 2022-08-25
US20230058425A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
JP6889171B2 (ja) Ｔｌｒ７アゴニスト結晶形ａ、その調製方法及び使用
US10968200B2 (en) Salts of an LSD1 inhibitor and processes for preparing the same
JP6898336B2 (ja) Ｔｌｒ７アゴニストのマレイン酸塩、その結晶形ｃ、ｄ及びｅ、マレイン酸塩及び結晶形の調製方法及び使用
JP6877450B2 (ja) Ｔｌｒ７アゴニストのトリフルオロ酢酸塩及びその結晶形ｂ、調製方法、並びに使用
CA3117849A1 (en) Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor
CN114929232A (zh) 一种吡啶并嘧啶类衍生物的结晶形式及其制备方法
CN110526918B (zh) 一种吡唑并杂芳基类衍生物的晶型及制备方法
TWI773987B (zh) 二胺基嘧啶類化合物或其水合物的固體形式及其製備方法和用途
CN115667246A (zh) 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用
EP3719013B1 (en) Pyrimidine sulfamide derivative and preparation method and medical application thereof
CN113461661B (zh) 6-(吡啶-3-基)喹唑啉-4(3h)-酮类衍生物及其制备和应用
EP4126842B1 (en) Trka inhibitor
CA3216045A1 (en) Compounds as pd1/pd-l1 inhibitors and methods thereof
CN110194741B (zh) 4-苯甲酰哌嗪-3-硝基-1,8-萘酰亚胺衍生物及其制备方法和应用
CN111819178B (zh) 一种吡唑并杂芳基类衍生物盐酸盐的晶型及制备方法
CN110526917B (zh) 一种吡唑并杂芳基类衍生物的可药用盐、晶型及其制备方法
CN110483520B (zh) 布鲁顿酪氨酸激酶抑制剂的晶型、制备方法及其应用
EP4122931A1 (en) Crystalline form of tlr8 agonist
WO2007039581A1 (en) Imidazolyl-substituted diazabenzophenone compounds
TW202337447A (zh) 含氮并環類衍生物抑制劑的酸式鹽或晶型及其製備方法和應用
CN116947890A (zh) 一种wee1抑制剂的三环化合物及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079606

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant